Plans for a clinical trial designed to overcome long-standing regulatory obstacles to the general clinical use of ultrasound contrast media in the U.S. have been knocked off track by an FDA-mandated black box safety warning for two microbubble agents approved for echocardiography.
Plans for a clinical trial designed to overcome long-standing regulatory obstacles to the general clinical use of ultrasound contrast media in the U.S. have been knocked off track by an FDA-mandated black box safety warning for two microbubble agents approved for echocardiography.
The black box warning for Bristol-Myers Squibb's Definity and GE Healthcare's Optison agents-issued Oct. 15-emphasizes the risk of serious cardiopulmonary reactions.
FDA representatives in 2006 had expressed general support for a draft plan from the American Institute of Ultrasound in Medicine for a clinical trial testing the efficacy of microbubble contrast for imaging transarterial chemoembolism of liver lesions. FDA officials suggested that the AIUM group use an approved cardiac agent (Definity or Optison) in its trial, according to Dr. Lennard Greenbaum, immediate past president of the AIUM.
"The black box ruling came as a total surprise," Greenbaum told Diagnostic Imaging. "At stake is whether ultrasound contrast agents will ever be used for a noncardiac indication."
The black box order followed reports of 11 deaths associated with the two agents. According to the order, four of those deaths were caused by cardiac arrest that occurred either during infusion or within 30 minutes after infusion of a microbubble ultrasound agent. FDA officials acknowledged during a November teleconference a lack of corresponding adverse reactions to microbubble contrast when administered for noncardiac indications.
Still, FDA officials turned down a request during the teleconference to waive its requirement for the black box warnings on microbubble contrast media to be used in the proposed AIUM trial. It also held to a rule requiring close patient monitoring in the 30 minutes following contrast administration.
"Some radiologists tell me there may be difficulty getting an institutional review board to approve a project associated with such a severe warning," Greenbaum said.
Dr. Michael L. Main, medical director of the electrocardiography lab at the Mid America Heart Institute, along with 160 cosigners, sent a letter in November to the FDA expressing concern about the black box warning. Main argued that the four patient deaths may have been caused by underlying cardiovascular disease. He also said that the deaths occurred over a six-year period while about two million doses of the ultrasound contrast media were administered. The data suggest an event rate for ultrasound microbubble contrast of one in 500,000 cases, which Main said compares well against the one in 2500 risk of cardiac death from exercise treadmill testing.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Finds Transvaginal Ultrasound Unreliable for Detecting Endometrial Cancer in Black Patients
July 3rd 2024Utilizing a threshold of less than 5 mm of ultrasound-measured endometrial thickness, the authors of a new study noted an 11.4 percent false-negative probability for endometrial cancer in Black patients.
New Study Shows Non-Radiologists Interpreting 28 Percent of Imaging for Medicare Patients
June 28th 2024While radiologists interpreted approximately 99 percent of all non-cardiac CT, MRI and nuclear medicine studies in hospital and emergency department settings for Medicare beneficiaries, new research shows significantly less radiologist review of cardiac imaging and office-based imaging.
FDA Clears Pocket-Sized ECG System and AI Technology for Detection of Cardiac Conditions
June 27th 2024Using a reduced leadset and deep neural network algorithms trained on more than 175 million electrocardiograms, the KAI 12L technology reportedly detects up to 35 cardiac determinations, including acute myocardial infarction.